[Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine

P. Riba, Yong Ben, Thi M D Nguyen, S. Fürst, Peter W. Schiller, Nancy M. Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The clinical effectiveness of morphine is limited by several side effects, including the development of tolerance and dependence. Most of these side effects are believed to be mediated by central opioid receptors; therefore, hydrophilic opioids, which don't cross the blood-brain barrier, may have advantages over morphine in some clinical applications. We recently synthesized several analogues of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a highly hydrophilic peptide derived from the endogenous opioid peptide dermorphin; all of them, particularly [Dmt1] DALDA (Dmt - 2′,6′-dimethyl tyrosine), had high potency and selectivity at μ receptors, the target of morphine, in activity assays.1 Here we report the pharmacological characterization of [Dmt1] DALDA in the whole animal. [Dmt1]]DALDA was 40 times more potent than morphine in inducing antinociception in mice when both drugs were given s.c., and 6-14 times more potent than DAMGO, a selective μ agonist, when both drugs were given it. However, [Dmt1]DALDA showed poor cross-tolerance to morphine; thus chronic morphine treatment of animals increased the antinociceptive AD50 of systemic [Dmt1]DALDA two fold or less, as compared to an 8-9-fold increase for morphine and a 4-5-fold increase for DAMGO. The antinociceptive activity of [Dmt1]DALDA (i.t) was blocked by CTAP, a selective μ antagonist, but not by TIPPψ, a selective δ antagonist, nor by nor-BNI, a selective κ antagonist. [Dmt1]DALDA-induced antinociception was also blocked by naloxone methiodide, an antagonist that does not cross the blood-brain barrier, when agonist and antagonist were given i.t. or i.c.v., but not when they were given s.c. We conclude that [Dmt1] DALDA is a highly potent analgesic acting at μ receptors. Though it appears to penetrate the blood-brain barrier, it exhibits low cross-tolerance to morphine, suggesting that it may have advantages over the latter in certain clinical applications.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalCurrent Medicinal Chemistry
Volume9
Issue number1
Publication statusPublished - 2002

Fingerprint

Opioid Receptors
Morphine
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Blood-Brain Barrier
Animals
tyrosyl-arginyl-phenylalanyl-lysinamide
Opioid Peptides
mu Opioid Receptor
Pharmaceutical Preparations
Opioid Analgesics
Tyrosine
Analgesics
Pharmacology
Peptides

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

[Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine. / Riba, P.; Ben, Yong; Nguyen, Thi M D; Fürst, S.; Schiller, Peter W.; Lee, Nancy M.

In: Current Medicinal Chemistry, Vol. 9, No. 1, 2002, p. 31-39.

Research output: Contribution to journalArticle

Riba, P. ; Ben, Yong ; Nguyen, Thi M D ; Fürst, S. ; Schiller, Peter W. ; Lee, Nancy M. / [Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine. In: Current Medicinal Chemistry. 2002 ; Vol. 9, No. 1. pp. 31-39.
@article{47658da7813542c1826dd16e3a59b467,
title = "[Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine",
abstract = "The clinical effectiveness of morphine is limited by several side effects, including the development of tolerance and dependence. Most of these side effects are believed to be mediated by central opioid receptors; therefore, hydrophilic opioids, which don't cross the blood-brain barrier, may have advantages over morphine in some clinical applications. We recently synthesized several analogues of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a highly hydrophilic peptide derived from the endogenous opioid peptide dermorphin; all of them, particularly [Dmt1] DALDA (Dmt - 2′,6′-dimethyl tyrosine), had high potency and selectivity at μ receptors, the target of morphine, in activity assays.1 Here we report the pharmacological characterization of [Dmt1] DALDA in the whole animal. [Dmt1]]DALDA was 40 times more potent than morphine in inducing antinociception in mice when both drugs were given s.c., and 6-14 times more potent than DAMGO, a selective μ agonist, when both drugs were given it. However, [Dmt1]DALDA showed poor cross-tolerance to morphine; thus chronic morphine treatment of animals increased the antinociceptive AD50 of systemic [Dmt1]DALDA two fold or less, as compared to an 8-9-fold increase for morphine and a 4-5-fold increase for DAMGO. The antinociceptive activity of [Dmt1]DALDA (i.t) was blocked by CTAP, a selective μ antagonist, but not by TIPPψ, a selective δ antagonist, nor by nor-BNI, a selective κ antagonist. [Dmt1]DALDA-induced antinociception was also blocked by naloxone methiodide, an antagonist that does not cross the blood-brain barrier, when agonist and antagonist were given i.t. or i.c.v., but not when they were given s.c. We conclude that [Dmt1] DALDA is a highly potent analgesic acting at μ receptors. Though it appears to penetrate the blood-brain barrier, it exhibits low cross-tolerance to morphine, suggesting that it may have advantages over the latter in certain clinical applications.",
author = "P. Riba and Yong Ben and Nguyen, {Thi M D} and S. F{\"u}rst and Schiller, {Peter W.} and Lee, {Nancy M.}",
year = "2002",
language = "English",
volume = "9",
pages = "31--39",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - [Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine

AU - Riba, P.

AU - Ben, Yong

AU - Nguyen, Thi M D

AU - Fürst, S.

AU - Schiller, Peter W.

AU - Lee, Nancy M.

PY - 2002

Y1 - 2002

N2 - The clinical effectiveness of morphine is limited by several side effects, including the development of tolerance and dependence. Most of these side effects are believed to be mediated by central opioid receptors; therefore, hydrophilic opioids, which don't cross the blood-brain barrier, may have advantages over morphine in some clinical applications. We recently synthesized several analogues of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a highly hydrophilic peptide derived from the endogenous opioid peptide dermorphin; all of them, particularly [Dmt1] DALDA (Dmt - 2′,6′-dimethyl tyrosine), had high potency and selectivity at μ receptors, the target of morphine, in activity assays.1 Here we report the pharmacological characterization of [Dmt1] DALDA in the whole animal. [Dmt1]]DALDA was 40 times more potent than morphine in inducing antinociception in mice when both drugs were given s.c., and 6-14 times more potent than DAMGO, a selective μ agonist, when both drugs were given it. However, [Dmt1]DALDA showed poor cross-tolerance to morphine; thus chronic morphine treatment of animals increased the antinociceptive AD50 of systemic [Dmt1]DALDA two fold or less, as compared to an 8-9-fold increase for morphine and a 4-5-fold increase for DAMGO. The antinociceptive activity of [Dmt1]DALDA (i.t) was blocked by CTAP, a selective μ antagonist, but not by TIPPψ, a selective δ antagonist, nor by nor-BNI, a selective κ antagonist. [Dmt1]DALDA-induced antinociception was also blocked by naloxone methiodide, an antagonist that does not cross the blood-brain barrier, when agonist and antagonist were given i.t. or i.c.v., but not when they were given s.c. We conclude that [Dmt1] DALDA is a highly potent analgesic acting at μ receptors. Though it appears to penetrate the blood-brain barrier, it exhibits low cross-tolerance to morphine, suggesting that it may have advantages over the latter in certain clinical applications.

AB - The clinical effectiveness of morphine is limited by several side effects, including the development of tolerance and dependence. Most of these side effects are believed to be mediated by central opioid receptors; therefore, hydrophilic opioids, which don't cross the blood-brain barrier, may have advantages over morphine in some clinical applications. We recently synthesized several analogues of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a highly hydrophilic peptide derived from the endogenous opioid peptide dermorphin; all of them, particularly [Dmt1] DALDA (Dmt - 2′,6′-dimethyl tyrosine), had high potency and selectivity at μ receptors, the target of morphine, in activity assays.1 Here we report the pharmacological characterization of [Dmt1] DALDA in the whole animal. [Dmt1]]DALDA was 40 times more potent than morphine in inducing antinociception in mice when both drugs were given s.c., and 6-14 times more potent than DAMGO, a selective μ agonist, when both drugs were given it. However, [Dmt1]DALDA showed poor cross-tolerance to morphine; thus chronic morphine treatment of animals increased the antinociceptive AD50 of systemic [Dmt1]DALDA two fold or less, as compared to an 8-9-fold increase for morphine and a 4-5-fold increase for DAMGO. The antinociceptive activity of [Dmt1]DALDA (i.t) was blocked by CTAP, a selective μ antagonist, but not by TIPPψ, a selective δ antagonist, nor by nor-BNI, a selective κ antagonist. [Dmt1]DALDA-induced antinociception was also blocked by naloxone methiodide, an antagonist that does not cross the blood-brain barrier, when agonist and antagonist were given i.t. or i.c.v., but not when they were given s.c. We conclude that [Dmt1] DALDA is a highly potent analgesic acting at μ receptors. Though it appears to penetrate the blood-brain barrier, it exhibits low cross-tolerance to morphine, suggesting that it may have advantages over the latter in certain clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=0036230489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036230489&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 31

EP - 39

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 1

ER -